Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1 Study of FOR46 Administered Every 21 Days in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2018-112
    NCT ID
    • NCT03650491
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator
    • Jeffrey
      Zonder, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    Primary Objectives - Dose Escalation Period
    • Evaluate the safety and tolerability of FOR46 at escalating dose levels and administered IV every 21 days in RRMM patients.
    • Determine the MTD and/or the RP2D of FOR46 administered IV every 21 days in RRMM patients.
    Primary Objectives - Dose Expansion Period
    • Continue to evaluate the safety profile of FOR46 at the dose level selected for the dose-expansion period.
    • Evaluate the antimyeloma activity of FOR46 in RRMM patients, as assessed by the modified International Myeloma Working Group (IMWG) consensus criteria
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266